Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Non-Current Deffered Revenue (2018 - 2025)

Dianthus Therapeutics has reported Non-Current Deffered Revenue over the past 7 years, most recently at $6.1 million for Q3 2025.

  • Quarterly results put Non-Current Deffered Revenue at $6.1 million for Q3 2025, up 848.12% from a year ago — trailing twelve months through Sep 2025 was $6.1 million (up 848.12% YoY), and the annual figure for FY2024 was $1.9 million, changed.
  • Non-Current Deffered Revenue for Q3 2025 was $6.1 million at Dianthus Therapeutics, up from $1.8 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for DNTH hit a ceiling of $6.1 million in Q3 2025 and a floor of $640000.0 in Q3 2024.
  • Median Non-Current Deffered Revenue over the past 4 years was $791000.0 (2022), compared with a mean of $1.7 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: dropped 14.09% in 2024 and later soared 848.12% in 2025.
  • Dianthus Therapeutics' Non-Current Deffered Revenue stood at $791000.0 in 2022, then decreased by 5.82% to $745000.0 in 2023, then skyrocketed by 156.11% to $1.9 million in 2024, then soared by 218.03% to $6.1 million in 2025.
  • The last three reported values for Non-Current Deffered Revenue were $6.1 million (Q3 2025), $1.8 million (Q2 2025), and $1.9 million (Q1 2025) per Business Quant data.